Media Coverage
Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xb3 TM-001 in Brain Cancer
Bioasis Technologies and testing services provider BioAgilytix will partner on the development and validation of bioanalytical methods to support and advance the xB3 -001 program, Bioasis’ lead candidate to treat HER2+ brain cancer.
![Investing.com logo](https://www.bioagilytix.com/wp-content/uploads/2023/06/Screen-Shot-2018-08-22-at-4.43.14-PM.png)